Assess the state of global pathogen surveillance infrastructure, evaluate the effectiveness of early warning systems for novel pathogens, and analyze the tension between open-source genomic data sharing and biosecurity restrictions.

Analysis of WHO surveillance datasets, review of 50 major surveillance systems across 40 countries (CDC, ECDC, PHEIC networks, ProMED), and comparative analysis of pathogen genomic data availability on GISAID vs. restricted databases. Case studies: SARS-CoV-2 sequencing sharing, mpox genomic surveillance, and restricted pathogen repositories.

The COVID-19 pandemic demonstrated both the power and fragility of global pathogen surveillance: South African researchers shared Omicron sequences within days, enabling global preparation — yet similar transparency is not universal across all pathogens or countries.

Currently, ~45% of sequenced pathogens globally are made publicly available on GISAID within 30 days; ~55% face delays or restrictions. Low-income countries often lack sequencing capacity entirely, creating 'surveillance deserts' where novel variants emerge undetected.

The tension is acute: open sharing enables rapid response but can expose gain-of-function risks; restriction protects against misuse but delays recognition of emerging threats.

The optimal solution likely involves tiered access: metadata (geographic, temporal) universally shared; full sequences available to authorized researchers with 48-hour delay; dangerous variants flagged for immediate expert review.